Rituximab plus lenalidomide, methotrexate, and temozolomide for brain lymphoma
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 70 years old
- Your lymphoma started in the brain, spinal cord, meninges, or eye, with no spread to other body parts
- You have not had anti-cancer treatment before (other than surgery/biopsy and steroid medicine for symptom relief)
- You have at least one measurable (trackable) tumor area
- Your general health is good enough for treatment (ECOG 0–2, or possibly ECOG 3 if the doctor confirms it’s only due to the tumor)
- You can safely take study medicines (adequate organ function) and have no key exclusion health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial compares two treatment combinations for newly diagnosed primary CNS lymphoma (PCNSL), a rare type of brain lymphoma. It tests whether adding a drug called PD-1 (a type of immunotherapy that helps your immune system fight cancer) to the standard chemotherapy (R-MA) improves outcomes compared to R-MA alone. Participating gives access to a novel combination that may be more effective, though it involves extra monitoring and possible immune-related side effects.
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.